Expertise in
7
conditions

Jean-marc M. Gornet

Paris, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
Paris, FR 

Overview

Jean-marc Gornet practices in Paris, France. Gornet is highly rated in 7 conditions, according to our data. Their top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Colitis, Ileostomy, and Colonoscopy.

Their clinical research consists of co-authoring 89 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Paris, France
Other Locations
Clichy-sous-bois, France
Port-saint-louis-du-rhone, France
Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Enrollment Status: Recruiting
Publish Date: July 09, 2025
Intervention Type: Drug
Study Drugs: Oxaliplatin intravenous, 5 Fu, Folinic Acid, Oxaliplatin intra-arterial, Panitumumab, Bevacizumab
Study Phase: Phase 3
Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.
Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.
Enrollment Status: Unknown
Publish Date: March 12, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drugs: Azathioprine, Infliximab, Prednisolone, Hydrocortisone
Study Phase: Phase 4
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Drug
Study Drugs: Infliximab, Azathioprine, Mercaptopurine, Methotrexate
Study Phase: Phase 4
Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis
Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis
Enrollment Status: Completed
Publish Date: July 31, 2018
Intervention Type: Procedure
Study Phase: Not Applicable
View 4 Less Clinical Trials

89 Total Publications

Liver and peritoneal metastases of unknown primary site: French Intergroup Clinical Practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, SFP, SFR, ACHBT, SFRO, SNFCP, AFEF, RENAPE, NET-CAPI).
Liver and peritoneal metastases of unknown primary site: French Intergroup Clinical Practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, SFP, SFR, ACHBT, SFRO, SNFCP, AFEF, RENAPE, NET-CAPI).
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 13, 2026

Frequently Asked Questions about Jean-marc M. Gornet

Is Jean-marc M. Gornet a top-rated expert for Viral Gastroenteritis?

MediFind is an objective health platform that identifies experts based on real-world data. Jean-marc M. Gornet is classified as an Distinguished expert for Viral Gastroenteritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jean-marc M. Gornet participate in research or clinical trials?

Yes. Jean-marc M. Gornet has published 89 articles and abstracts on conditions like Viral Gastroenteritis. You can view a list of Jean-marc M. Gornet's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Gornet's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile